TW202400783A - 噬菌體 - Google Patents

噬菌體 Download PDF

Info

Publication number
TW202400783A
TW202400783A TW112115666A TW112115666A TW202400783A TW 202400783 A TW202400783 A TW 202400783A TW 112115666 A TW112115666 A TW 112115666A TW 112115666 A TW112115666 A TW 112115666A TW 202400783 A TW202400783 A TW 202400783A
Authority
TW
Taiwan
Prior art keywords
phage
genome
nucleic acid
specified
acid sequence
Prior art date
Application number
TW112115666A
Other languages
English (en)
Chinese (zh)
Inventor
安藤弘樹
松岡秀明
松川浩二
小野裕太郎
満仲翔一
Original Assignee
日商安斯泰來製藥股份有限公司
國立大學法人東海國立大學機構
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商安斯泰來製藥股份有限公司, 國立大學法人東海國立大學機構 filed Critical 日商安斯泰來製藥股份有限公司
Publication of TW202400783A publication Critical patent/TW202400783A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW112115666A 2022-04-28 2023-04-27 噬菌體 TW202400783A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022075078 2022-04-28
JP2022-075078 2022-04-28

Publications (1)

Publication Number Publication Date
TW202400783A true TW202400783A (zh) 2024-01-01

Family

ID=88518795

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112115666A TW202400783A (zh) 2022-04-28 2023-04-27 噬菌體

Country Status (5)

Country Link
EP (1) EP4516898A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2023210732A1 (cg-RX-API-DMAC7.html)
AR (1) AR129166A1 (cg-RX-API-DMAC7.html)
TW (1) TW202400783A (cg-RX-API-DMAC7.html)
WO (1) WO2023210732A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122060690A (zh) * 2026-04-01 2026-05-19 深圳市百泽诺科生物技术有限公司 一种分枝杆菌噬菌体及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4745231A1 (en) * 2023-07-14 2026-05-20 Arrowsmith Inc. MODIFIED BACTERIOPHAGE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010043924A1 (en) * 1994-04-05 2001-11-22 Exponential Biotherapies, Inc. Antibacterial therapy with bacteriophage physico-chemically altered to delay inactivation by the host defense system
EP2579883A1 (en) * 2010-06-08 2013-04-17 Leah Robert Bacteriophages for use against bacterial infections
EP3358015A1 (en) * 2017-02-03 2018-08-08 Eligo Bioscience Optimized vector for delivery in microbial populations
US11066691B1 (en) * 2018-09-14 2021-07-20 National Technology & Engineering Solutions Of Sandia, Llc Therapeutic phages and methods thereof
US12576118B2 (en) * 2019-05-21 2026-03-17 University of Pittsburgh—of the Commonwealth System of Higher Education Bacteriophages for the treatment of tuberculosis
CN114981408A (zh) * 2019-11-06 2022-08-30 洛可斯生物科学公司 Crispr cas系统和溶原性模块
WO2021092362A1 (en) * 2019-11-07 2021-05-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of specific phages for the treatment of nontuberculous mycobacteria (ntm) infections

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122060690A (zh) * 2026-04-01 2026-05-19 深圳市百泽诺科生物技术有限公司 一种分枝杆菌噬菌体及其应用

Also Published As

Publication number Publication date
AR129166A1 (es) 2024-07-24
EP4516898A4 (en) 2026-05-06
EP4516898A1 (en) 2025-03-05
WO2023210732A1 (ja) 2023-11-02
JPWO2023210732A1 (cg-RX-API-DMAC7.html) 2023-11-02

Similar Documents

Publication Publication Date Title
US8105579B2 (en) Bacteriophage-containing therapeutic agents
DE60113851T2 (de) Bakteriophage mit breitem wirtsspektrum
US20130295054A1 (en) Modified Bacteria and their Uses thereof for the Treatment of Cancer or Tumor
JP2020143119A (ja) シュードモナス感染症のファージ治療
JP2023182703A (ja) Staphylococcus感染症を処置するための治療的バクテリオファージ組成物
US20250170195A1 (en) Bacteriophage compositions for treating pseudomonas infections
EP4516898A1 (en) Bacteriophage
Adamczyk-Popławska et al. The potential for bacteriophages and prophage elements in fighting and preventing the gonorrhea
WO2025018295A1 (ja) 改変バクテリオファージ
Hoyle et al. Phage therapy: bacteriophages as natural, self-replicating antimicrobials
KR100949389B1 (ko) 박테리오파지 kctc11120bp를 함유하는 세균증식 억제 또는 사멸용 제제
RU2717973C1 (ru) Штамм бактериофага Pseudomonas aeruginosa N 322 (500316), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717451C1 (ru) Штамм бактериофага Pseudomonas aeruginosa N 323 (500317), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
US12576118B2 (en) Bacteriophages for the treatment of tuberculosis
RU2831173C1 (ru) Штамм бактериофага Pseudomonas phage Ka1 для лечения и/или профилактики инфекционных заболеваний, вызываемых Pseudomonas aeruginosa
Ghazaei A Comprehensive Review of Therapeutics Targeting Intracellular Bacteria: Current Insights and Emerging Approaches
RU2808830C1 (ru) Штамм бактериофага Pseudomonas phage Ka2 для профилактики и лечения инфекционных заболеваний, вызываемых Pseudomonas aeruginosa
RU2717972C1 (ru) Штамм бактериофага Pseudomonas aeruginosa N 324 (500318), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
US20250051733A1 (en) Method of Generating Phage Clones with Expanded Activity
RU2717435C1 (ru) Штамм бактериофага Pseudomonas aeruginosa N 326 (500320), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
RU2717026C1 (ru) Штамм бактериофага Pseudomonas aeruginosa N 325 (500319), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
EP4720263A1 (en) Phage therapy utilizing a unique cocktail of pseudomonas aeruginosa phages
De Soir Exploring Phage-Antibiotic Synergies for the Treatment of Biofilm-related Infectious Diseases
Yıldırım Mediterr J Infect Microb Antimicrob 2022; 11: 43 Erişim: http://dx. doi. org/10.4274/mjima. galenos. 2022.2022. 43
Abdo Ahmad Establishment of a Bacteriophages Platform: Alternative Therapeutic Option